Hackstein Holger, Thomson Angus W
Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Langhansstr. 7, D-35392 Giessen, Germany.
Nat Rev Immunol. 2004 Jan;4(1):24-34. doi: 10.1038/nri1256.
Immunosuppressive drugs have revolutionized organ transplantation and improved the therapeutic management of autoimmune diseases. The development of immunosuppressive drugs and understanding of their action traditionally has been focused on lymphocytes, but recent evidence indicates that these agents interfere with immune responses at the earliest stage, targeting key functions of dendritic cells (DCs). Here, we review our present understanding of how classical and new immunosuppressive agents interfere with DC development and function. This knowledge might provide a rational basis for the selection of immunosuppressive drugs in different clinical settings and for the generation of tolerogenic DCs in the laboratory.
免疫抑制药物彻底改变了器官移植，并改善了自身免疫性疾病的治疗管理。传统上，免疫抑制药物的研发及其作用机制的研究主要集中在淋巴细胞上，但最近的证据表明，这些药物在最早阶段就干扰免疫反应，靶向树突状细胞（DCs）的关键功能。在此，我们综述了目前对经典和新型免疫抑制药物如何干扰DC发育和功能的理解。这些知识可能为在不同临床环境中选择免疫抑制药物以及在实验室中生成耐受性DC提供合理依据。
